Sawada T, Kurano M, Shirai H, et al. - In this investigation, researchers evaluated the usefulness of serum levels of phosphatidylserine-specific phospholipase A1 (PS-PLA₁), a lipase involved in the production of lysophosphatidylserine with multi-immunomodulatory effects, in systemic lupus erythematosus (SLE). They measured serum PS-PLA₁ in 161 SLE patients, 80 disease controls, and 237 healthy controls. In SLE patients, serum PS-PLA₁ was significantly higher than in healthy controls, RA and SS patients. PS-PLA₁ was significantly associated with SLE Disease Activity Index (SLEDAI) and immunoglobulin G (IgG) and was inversely linked to white blood cell counts, lymphocyte counts, total complement hemolytic activity (CH50), complements C3, and C4 in patients with SLE overall. The authors concluded that serum PS-PLA₁ is related to SLE's disease activity, indicating its potential use as a biomarker to monitor the activity of SLE disease.